Induction of CNS α-synuclein pathology by fibrillar and non-amyloidogenic recombinant α-synuclein

Table 1 Summary of neonatal nTg mice injected with αS proteins ^a

Mouse strain	Inoculum	Age at harvest	Number of mice	Pathological findings
C57BL6/C3H	fib αS (2 μl of 1 mg/ml)	1 month	9	No inclusions
C57BL6/C3H	fib αS (2 μl of 1 mg/ml)	2 months	3	No inclusions
C57BL6/C3H	fib αS (2 μl of 1 mg/ml)	4 months	6	No inclusions
C57BL6/C3H	fib αS (2 μl of 1 mg/ml)	8 months	4	No inclusions
C57BL6/C3H	fib αS (5 μl of 5 mg/ml)	1 month	9	No inclusions
C57BL6/C3H	fib αS (5 μl of 5 mg/ml)	2 months	7	1 of 7 mice show rare inclusions^b
C57BL6/C3H	fib αS (5 μl of 5 mg/ml)	4 months	3	No inclusions
C57BL6/C3H	fib αS (5 μl of 5 mg/ml)	8 months	13	4 of 13 mice show rare cortical inclusions^c
C57BL6/C3H	Δ71-82 αS (2 μl of 1 mg/ml)	1 month	4	No inclusions
C57BL6/C3H	Δ71-82 αS (2 μl of 1 mg/ml)	2 months	3	No inclusions
C57BL6/C3H	Δ71-82 αS (2 μl of 1 mg/ml)	4 months	2	No inclusions
C57BL6/C3H	Δ71-82 αS (5 μl of 5 mg/ml)	1 month	9	No inclusions
C57BL6/C3H	Δ71-82 αS (5 μl of 5 mg/ml)	2 months	8	No inclusions
C57BL6/C3H	Δ71-82 αS (5 μl of 5 mg/ml)	8 months	6	No inclusions

^anTg mice were injected with 21–140 human αS fibrils (fib) or Δ71-82 human αS at the different dosages indicated and analyzed for αS pathology at 1–8 months post-injection using pSer129 and Syn506 antibodies.
^bSparse inclusions were observed in the midbrain area of 1 mouse.
^c See Figure 2 for a schematic neuroanatomical map showing the distribution of αS pathology.

ISSN: 2051-5960